Clinical trial of Tinidazole (Fasigyn) in acute and chronic intestinal amoebiasis.
10.3347/kjp.1974.12.2.135
- Author:
Jung Kyoo LIM
1
Author Information
1. Department of Pharmacology, College of Medicine, Seoul National University, Korea.
- Publication Type:Original Article
- MeSH:
parasitology-protozoa-Entamoeba histolytica;
chemotherapy-Tinidazole;
drug;
Tinidazole
- From:The Korean Journal of Parasitology
1974;12(2):135-140
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tinidazole (Fasigyn), a new drug which is active in vitro and in vivo against Entamoeba histolytica, was used in 30 Korean patients with acute and chronic intestinal amoebiasis. In aute amoebic dysentry eight of ten patients given tinidazole 150 mg q.i.d. for 10 days were cured clinically and parasitologically. In chronic intestinal amoebiasis, the parasitological cure was obtained 6 out of 10 patients given150 mg q.i.d. for 10 days and 8 out of 10 in patients given 300 mg q.i.d. for 7 days. Tinidazole is well tolerated and is free from serious toxicity. There was no significant alteration in blood count, liver function tests and urine analysis of any of the patients treated with tinidazole.
